메뉴 건너뛰기




Volumn 11, Issue 4, 2005, Pages 496-507

Genetically based therapeutics for cancer: Similarities and contrasts with traditional drug discovery and development

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTISENSE OLIGONUCLEOTIDE; BEVACIZUMAB; CETUXIMAB; CISPLATIN; EDRECOLOMAB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FLUOROURACIL; GEFITINIB; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IBRITUMOMAB TIUXETAN; IMATINIB; INTERLEUKIN 2; NEW DRUG; ONCOLYTIC VIRUS; ONYX 015; PLASMID VECTOR; PROTEIN P53; RIBOZYME; RITUXIMAB; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; TRASTUZUMAB; TUMOR NECROSIS FACTOR; VASCULOTROPIN ANTIBODY; VIRUS VECTOR;

EID: 14844352335     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ymthe.2004.12.004     Document Type: Review
Times cited : (16)

References (124)
  • 1
    • 0037169357 scopus 로고    scopus 로고
    • Cancer as a complex genetic trait: Tumor susceptibility in humans and mouse models
    • A. Balmain Cancer as a complex genetic trait: Tumor susceptibility in humans and mouse models Cell 108 2002 145-152
    • (2002) Cell , vol.108 , pp. 145-152
    • Balmain, A.1
  • 2
    • 0042881036 scopus 로고    scopus 로고
    • Cancer susceptibility in the mouse: Genetics, biology and implications for human cancer
    • P. Demant Cancer susceptibility in the mouse: Genetics, biology and implications for human cancer Nat. Rev. Genet. 4 2003 721-734
    • (2003) Nat. Rev. Genet. , vol.4 , pp. 721-734
    • Demant, P.1
  • 3
    • 0037732512 scopus 로고    scopus 로고
    • 10 years of mouse cancer modifier loci: Human relevance
    • T.A. Dragani 10 years of mouse cancer modifier loci: Human relevance Cancer Res. 63 2003 3011-3018
    • (2003) Cancer Res. , vol.63 , pp. 3011-3018
    • Dragani, T.A.1
  • 4
    • 0034460530 scopus 로고    scopus 로고
    • Genomics and proteomics: The new millennium of drug discovery and development
    • M.J. Cunningham Genomics and proteomics: The new millennium of drug discovery and development J. Pharmacol. Toxicol. Methods 44 2000 291-300
    • (2000) J. Pharmacol. Toxicol. Methods , vol.44 , pp. 291-300
    • Cunningham, M.J.1
  • 5
    • 0035892305 scopus 로고    scopus 로고
    • Gene expression microarray analysis in cancer biology, pharmacology, and drug development: Progress and potential
    • P.A. Clarke R. te Poele R. Wooster P. Workman Gene expression microarray analysis in cancer biology, pharmacology, and drug development: Progress and potential Biochem. Pharmacol. 62 2001 1311-1336
    • (2001) Biochem. Pharmacol. , vol.62 , pp. 1311-1336
    • Clarke, P.A.1    te Poele, R.2    Wooster, R.3    Workman, P.4
  • 6
    • 0036549767 scopus 로고    scopus 로고
    • Discordant protein and mRNA expression in lung adenocarcinomas
    • G. Chen et al. Discordant protein and mRNA expression in lung adenocarcinomas Mol. Cell. Proteom. 1 2002 304-313
    • (2002) Mol. Cell. Proteom. , vol.1 , pp. 304-313
    • Chen, G.1
  • 7
    • 0030895921 scopus 로고    scopus 로고
    • A comparison of selected mRNA and protein abundances in human liver
    • L. Anderson J. Seilhamer A comparison of selected mRNA and protein abundances in human liver Electrophoresis 18 1997 533-537
    • (1997) Electrophoresis , vol.18 , pp. 533-537
    • Anderson, L.1    Seilhamer, J.2
  • 8
    • 0032979179 scopus 로고    scopus 로고
    • Protein analysis by mass spectrometry and sequence database searching: Tools for cancer research in the post-genomic era
    • S.P. Gygi D.K. Han A.C. Gingras N. Sonenberg R. Aebersold Protein analysis by mass spectrometry and sequence database searching: Tools for cancer research in the post-genomic era Electrophoresis 20 1999 310-319
    • (1999) Electrophoresis , vol.20 , pp. 310-319
    • Gygi, S.P.1    Han, D.K.2    Gingras, A.C.3    Sonenberg, N.4    Aebersold, R.5
  • 9
    • 0037309124 scopus 로고    scopus 로고
    • Novel approaches to map protein interactions
    • D. Figeys Novel approaches to map protein interactions Curr. Opin. Biotechnol. 14 2003 119-125
    • (2003) Curr. Opin. Biotechnol. , vol.14 , pp. 119-125
    • Figeys, D.1
  • 11
    • 0037434980 scopus 로고    scopus 로고
    • From genomics to proteomics
    • M. Tyers M. Mann From genomics to proteomics Nature 422 2003 193-197
    • (2003) Nature , vol.422 , pp. 193-197
    • Tyers, M.1    Mann, M.2
  • 13
    • 0037441560 scopus 로고    scopus 로고
    • Fulfilling the promise: Drug discovery in the post-genomic era
    • S.K. Chanda J.S. Caldwell Fulfilling the promise: Drug discovery in the post-genomic era Drug Discovery Today 8 2003 168-174
    • (2003) Drug Discovery Today , vol.8 , pp. 168-174
    • Chanda, S.K.1    Caldwell, J.S.2
  • 15
    • 1342287074 scopus 로고    scopus 로고
    • Novel angiogenic signaling pathways and vascular targets
    • R. Bicknell A.L. Harris Novel angiogenic signaling pathways and vascular targets Annu. Rev. Pharmacol. Toxicol. 44 2004 219-238
    • (2004) Annu. Rev. Pharmacol. Toxicol. , vol.44 , pp. 219-238
    • Bicknell, R.1    Harris, A.L.2
  • 16
    • 0042386124 scopus 로고    scopus 로고
    • Caveolae: Mining little caves for new cancer targets
    • L.A. Carver J.E. Schnitzer Caveolae: Mining little caves for new cancer targets Nat. Rev. Cancer 3 2003 571-581
    • (2003) Nat. Rev. Cancer , vol.3 , pp. 571-581
    • Carver, L.A.1    Schnitzer, J.E.2
  • 17
    • 2442620564 scopus 로고    scopus 로고
    • Tumor endothelial markers: New targets for cancer therapy
    • A. Nanda B. St Croix Tumor endothelial markers: New targets for cancer therapy Curr. Opin. Oncol. 16 2004 44-49
    • (2004) Curr. Opin. Oncol. , vol.16 , pp. 44-49
    • Nanda, A.1    St Croix, B.2
  • 18
    • 2642571660 scopus 로고    scopus 로고
    • Vascular-targeting therapies for treatment of malignant disease
    • D.W. Siemann D.J. Chaplin M.R. Horsman Vascular-targeting therapies for treatment of malignant disease Cancer 100 2004 2491-2499
    • (2004) Cancer , vol.100 , pp. 2491-2499
    • Siemann, D.W.1    Chaplin, D.J.2    Horsman, M.R.3
  • 19
    • 1642555578 scopus 로고    scopus 로고
    • Cancer metastasis therapeutic targets and drug discovery: Emerging small-molecule protein kinase inhibitors
    • T.K. Sawyer Cancer metastasis therapeutic targets and drug discovery: emerging small-molecule protein kinase inhibitors Expert Opin. Invest. Drugs 13 2004 1-19
    • (2004) Expert Opin. Invest. Drugs , vol.13 , pp. 1-19
    • Sawyer, T.K.1
  • 21
    • 0037192458 scopus 로고    scopus 로고
    • Matrix metalloproteinase inhibitors and cancer: Trials and tribulations
    • L.M. Coussens B. Fingleton L.M. Matrisian Matrix metalloproteinase inhibitors and cancer: Trials and tribulations Science 295 2002 2387-2392
    • (2002) Science , vol.295 , pp. 2387-2392
    • Coussens, L.M.1    Fingleton, B.2    Matrisian, L.M.3
  • 22
    • 0037312899 scopus 로고    scopus 로고
    • The not-so innocent bystander: The microenvironment as a therapeutic target in cancer
    • A.C. Erickson M.H. Barcellos-Hoff The not-so innocent bystander: The microenvironment as a therapeutic target in cancer Expert Opin. Ther. Targets 7 2003 71-88
    • (2003) Expert Opin. Ther. Targets , vol.7 , pp. 71-88
    • Erickson, A.C.1    Barcellos-Hoff, M.H.2
  • 23
    • 2342637653 scopus 로고    scopus 로고
    • Matrix metalloproteinase inhibitors
    • N. Ramnath P.J. Creaven Matrix metalloproteinase inhibitors Curr. Oncol. Rep. 6 2004 96-102
    • (2004) Curr. Oncol. Rep. , vol.6 , pp. 96-102
    • Ramnath, N.1    Creaven, P.J.2
  • 24
    • 0038265104 scopus 로고    scopus 로고
    • The extracellular matrix: A new turn-of-the-screw for anti-angiogenic strategies
    • L. Sanz L. Alvarez-Vallina The extracellular matrix: A new turn-of-the-screw for anti-angiogenic strategies Trends Mol. Med. 9 2003 256-262
    • (2003) Trends Mol. Med. , vol.9 , pp. 256-262
    • Sanz, L.1    Alvarez-Vallina, L.2
  • 25
    • 1642471690 scopus 로고    scopus 로고
    • Pharmacological modulation of local feedback mechanisms as a therapeutic approach in breast cancer treatment
    • C.F. Singer G. Hudelist A. Galid E. Kubista Pharmacological modulation of local feedback mechanisms as a therapeutic approach in breast cancer treatment Drugs Today (Barcelona) 39 2003 917-926
    • (2003) Drugs Today (Barcelona) , vol.39 , pp. 917-926
    • Singer, C.F.1    Hudelist, G.2    Galid, A.3    Kubista, E.4
  • 26
    • 0036992758 scopus 로고    scopus 로고
    • Prostate tumor-stroma interaction: Molecular mechanisms and opportunities for therapeutic targeting
    • S.Y. Sung L.W. Chung Prostate tumor-stroma interaction: Molecular mechanisms and opportunities for therapeutic targeting Differentiation 70 2002 506-521
    • (2002) Differentiation , vol.70 , pp. 506-521
    • Sung, S.Y.1    Chung, L.W.2
  • 27
    • 0037052641 scopus 로고    scopus 로고
    • Matrix metalloproteinases in cancer: Prognostic markers and therapeutic targets
    • P. Vihinen V.M. Kahari Matrix metalloproteinases in cancer: Prognostic markers and therapeutic targets Int. J. Cancer 99 2002 157-166
    • (2002) Int. J. Cancer , vol.99 , pp. 157-166
    • Vihinen, P.1    Kahari, V.M.2
  • 28
    • 0032724911 scopus 로고    scopus 로고
    • Novel mechanisms for antisense-mediated regulation of gene expression
    • B.F. Baker B.P. Monia Novel mechanisms for antisense-mediated regulation of gene expression Biochim. Biophys. Acta 1489 1999 3-18
    • (1999) Biochim. Biophys. Acta , vol.1489 , pp. 3-18
    • Baker, B.F.1    Monia, B.P.2
  • 29
    • 0032700656 scopus 로고    scopus 로고
    • Molecular mechanisms of action of antisense drugs
    • S.T. Crooke Molecular mechanisms of action of antisense drugs Biochim. Biophys. Acta 1489 1999 31-44
    • (1999) Biochim. Biophys. Acta , vol.1489 , pp. 31-44
    • Crooke, S.T.1
  • 30
    • 0034176085 scopus 로고    scopus 로고
    • Elucidating cell signaling mechanisms using antisense technology
    • E. Koller W.A. Gaarde B.P. Monia Elucidating cell signaling mechanisms using antisense technology Trends Pharmacol. Sci. 21 2000 142-148
    • (2000) Trends Pharmacol. Sci. , vol.21 , pp. 142-148
    • Koller, E.1    Gaarde, W.A.2    Monia, B.P.3
  • 31
    • 0041422172 scopus 로고    scopus 로고
    • Ribozymes: A modern tool in medicine
    • A.U. Khan S.K. Lal Ribozymes: A modern tool in medicine J. Biomed. Sci. 10 2003 457-467
    • (2003) J. Biomed. Sci. , vol.10 , pp. 457-467
    • Khan, A.U.1    Lal, S.K.2
  • 32
    • 0027197245 scopus 로고
    • Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo
    • K.J. Kim et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo Nature 362 1993 841-844
    • (1993) Nature , vol.362 , pp. 841-844
    • Kim, K.J.1
  • 33
    • 0005620475 scopus 로고    scopus 로고
    • Aptamers as therapeutic and diagnostic agents
    • E.N. Brody L. Gold Aptamers as therapeutic and diagnostic agents J. Biotechnol. 74 2000 5-13
    • (2000) J. Biotechnol. , vol.74 , pp. 5-13
    • Brody, E.N.1    Gold, L.2
  • 34
  • 35
    • 0035807251 scopus 로고    scopus 로고
    • Peptide aptamers targeting the hepatitis B virus core protein: A new class of molecules with antiviral activity
    • K. Butz et al. Peptide aptamers targeting the hepatitis B virus core protein: A new class of molecules with antiviral activity Oncogene 20 2001 6579-6586
    • (2001) Oncogene , vol.20 , pp. 6579-6586
    • Butz, K.1
  • 36
    • 0037062951 scopus 로고    scopus 로고
    • RNA interference
    • G.J. Hannon RNA interference Nature 418 2002 244-251
    • (2002) Nature , vol.418 , pp. 244-251
    • Hannon, G.J.1
  • 38
    • 0035905766 scopus 로고    scopus 로고
    • Role for a bidentate ribonuclease in the initiation step of RNA interference
    • E. Bernstein A.A. Caudy S.M. Hammond G.J. Hannon Role for a bidentate ribonuclease in the initiation step of RNA interference Nature 409 2001 363-366
    • (2001) Nature , vol.409 , pp. 363-366
    • Bernstein, E.1    Caudy, A.A.2    Hammond, S.M.3    Hannon, G.J.4
  • 40
    • 12144289681 scopus 로고    scopus 로고
    • A large-scale RNAi screen in human cells identifies new components of the p53 pathway
    • K. Berns et al. A large-scale RNAi screen in human cells identifies new components of the p53 pathway Nature 428 2004 431-437
    • (2004) Nature , vol.428 , pp. 431-437
    • Berns, K.1
  • 41
    • 0034581163 scopus 로고    scopus 로고
    • Tet repressor-based system for regulated gene expression in eukaryotic cells: Principles and advances
    • U. Baron H. Bujard Tet repressor-based system for regulated gene expression in eukaryotic cells: Principles and advances Methods Enzymol. 327 2000 401-421
    • (2000) Methods Enzymol. , vol.327 , pp. 401-421
    • Baron, U.1    Bujard, H.2
  • 42
    • 0036549015 scopus 로고    scopus 로고
    • Conditional mouse models of sporadic cancer
    • J. Jonkers A. Berns Conditional mouse models of sporadic cancer Nat. Rev. Cancer 2 2002 251-265
    • (2002) Nat. Rev. Cancer , vol.2 , pp. 251-265
    • Jonkers, J.1    Berns, A.2
  • 43
    • 0035491607 scopus 로고    scopus 로고
    • Conditional control of gene expression in the mouse
    • M. Lewandoski Conditional control of gene expression in the mouse Nat. Rev. Genet. 2 2001 743-755
    • (2001) Nat. Rev. Genet. , vol.2 , pp. 743-755
    • Lewandoski, M.1
  • 44
    • 1542321226 scopus 로고    scopus 로고
    • Animal models of tumor immunity, immunotherapy and cancer vaccines
    • S. Ostrand-Rosenberg Animal models of tumor immunity, immunotherapy and cancer vaccines Curr. Opin. Immunol. 16 2004 143-150
    • (2004) Curr. Opin. Immunol. , vol.16 , pp. 143-150
    • Ostrand-Rosenberg, S.1
  • 46
  • 48
    • 0034470397 scopus 로고    scopus 로고
    • Angiogenesis in transgenic models of multistep carcinogenesis
    • D.A. MG T. Afanasieva A. Aguzzi Angiogenesis in transgenic models of multistep carcinogenesis J. Neurooncol. 50 2000 89-98
    • (2000) J. Neurooncol. , vol.50 , pp. 89-98
    • MG, D.A.1    Afanasieva, T.2    Aguzzi, A.3
  • 49
    • 0030512608 scopus 로고    scopus 로고
    • Transgenic mouse models of tumour angiogenesis: The angiogenic switch, its molecular controls, and prospects for preclinical therapeutic models
    • D. Hanahan G. Christofori P. Naik J. Arbeit Transgenic mouse models of tumour angiogenesis: The angiogenic switch, its molecular controls, and prospects for preclinical therapeutic models Eur. J. Cancer 32A 1996 2386-2393
    • (1996) Eur. J. Cancer , vol.32 A , pp. 2386-2393
    • Hanahan, D.1    Christofori, G.2    Naik, P.3    Arbeit, J.4
  • 50
    • 1942518888 scopus 로고    scopus 로고
    • Spontaneous and genetically engineered animal models: Use in preclinical cancer drug development
    • K. Hansen C. Khanna Spontaneous and genetically engineered animal models: Use in preclinical cancer drug development Eur. J. Cancer 40 2004 858-880
    • (2004) Eur. J. Cancer , vol.40 , pp. 858-880
    • Hansen, K.1    Khanna, C.2
  • 52
    • 0036840676 scopus 로고    scopus 로고
    • Small animal imaging. current technology and perspectives for oncological imaging
    • J.S. Lewis S. Achilefu J.R. Garbow R. Laforest M.J. Welch Small animal imaging. current technology and perspectives for oncological imaging Eur. J. Cancer 38 2002 2173-2188
    • (2002) Eur. J. Cancer , vol.38 , pp. 2173-2188
    • Lewis, J.S.1    Achilefu, S.2    Garbow, J.R.3    Laforest, R.4    Welch, M.J.5
  • 53
    • 0036359767 scopus 로고    scopus 로고
    • Scaling down imaging: Molecular mapping of cancer in mice
    • R. Weissleder Scaling down imaging: Molecular mapping of cancer in mice Nat. Rev. Cancer 2 2002 11-18
    • (2002) Nat. Rev. Cancer , vol.2 , pp. 11-18
    • Weissleder, R.1
  • 54
    • 84867502960 scopus 로고    scopus 로고
    • Tissue microarray (TMA) applications: Implications for molecular medicine
    • R. Simon G. Sauter Tissue microarray (TMA) applications: Implications for molecular medicine Expert Rev. Mol. Med. 2003 2003 1-12
    • (2003) Expert Rev. Mol. Med. , vol.2003 , pp. 1-12
    • Simon, R.1    Sauter, G.2
  • 55
    • 0034812398 scopus 로고    scopus 로고
    • Tissue microarray (TMA) technology: Miniaturized pathology archives for high-throughput in situ studies
    • L. Bubendorf A. Nocito H. Moch G. Sauter Tissue microarray (TMA) technology: Miniaturized pathology archives for high-throughput in situ studies J. Pathol. 195 2001 72-79
    • (2001) J. Pathol. , vol.195 , pp. 72-79
    • Bubendorf, L.1    Nocito, A.2    Moch, H.3    Sauter, G.4
  • 56
    • 0031822837 scopus 로고    scopus 로고
    • Tissue microarrays for high-throughput molecular profiling of tumor specimens
    • J. Kononen et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens Nat. Med. 4 1998 844-847
    • (1998) Nat. Med. , vol.4 , pp. 844-847
    • Kononen, J.1
  • 57
    • 0036603905 scopus 로고    scopus 로고
    • Chemical space navigation in lead discovery
    • T.I. Oprea Chemical space navigation in lead discovery Curr. Opin. Chem. Biol. 6 2002 384-389
    • (2002) Curr. Opin. Chem. Biol. , vol.6 , pp. 384-389
    • Oprea, T.I.1
  • 58
    • 0037376928 scopus 로고    scopus 로고
    • Pharmaceutical profiling in drug discovery
    • E.H. Kerns L. Di Pharmaceutical profiling in drug discovery Drug Discovery Today 8 2003 316-323
    • (2003) Drug Discovery Today , vol.8 , pp. 316-323
    • Kerns, E.H.1    Di, L.2
  • 59
    • 0037468884 scopus 로고    scopus 로고
    • A comparison of physiochemical property profiles of development and marketed oral drugs
    • M.C. Wenlock R.P. Austin P. Barton A.M. Davis P.D. Leeson A comparison of physiochemical property profiles of development and marketed oral drugs J. Med. Chem. 46 2003 1250-1256
    • (2003) J. Med. Chem. , vol.46 , pp. 1250-1256
    • Wenlock, M.C.1    Austin, R.P.2    Barton, P.3    Davis, A.M.4    Leeson, P.D.5
  • 60
    • 1242271305 scopus 로고    scopus 로고
    • Molecular recognition: The fragment approach in lead generation
    • D. Fattori Molecular recognition: The fragment approach in lead generation Drug Discovery Today 9 2004 229-238
    • (2004) Drug Discovery Today , vol.9 , pp. 229-238
    • Fattori, D.1
  • 61
    • 0038748179 scopus 로고    scopus 로고
    • Virtual screening of virtual libraries
    • D.V. Green Virtual screening of virtual libraries Prog. Med. Chem. 41 2003 61-97
    • (2003) Prog. Med. Chem. , vol.41 , pp. 61-97
    • Green, D.V.1
  • 63
    • 0041563779 scopus 로고    scopus 로고
    • Obstacles to cancer immunotherapy: Expression of membrane complement regulatory proteins (mCRPs) in tumors
    • Z. Fishelson N. Donin S. Zell S. Schultz M. Kirschfink Obstacles to cancer immunotherapy: Expression of membrane complement regulatory proteins (mCRPs) in tumors Mol. Immunol. 40 2003 109-123
    • (2003) Mol. Immunol. , vol.40 , pp. 109-123
    • Fishelson, Z.1    Donin, N.2    Zell, S.3    Schultz, S.4    Kirschfink, M.5
  • 64
    • 0036900866 scopus 로고    scopus 로고
    • Antibody manufacture in transgenic animals and comparisons with other systems
    • L.M. Houdebine Antibody manufacture in transgenic animals and comparisons with other systems Curr. Opin. Biotechnol. 13 2002 625-629
    • (2002) Curr. Opin. Biotechnol. , vol.13 , pp. 625-629
    • Houdebine, L.M.1
  • 65
    • 0036900286 scopus 로고    scopus 로고
    • Antibody discovery: The use of transgenic mice to generate human monoclonal antibodies for therapeutics
    • S.A. Kellermann L.L. Green Antibody discovery: The use of transgenic mice to generate human monoclonal antibodies for therapeutics Curr. Opin. Biotechnol. 13 2002 593-597
    • (2002) Curr. Opin. Biotechnol. , vol.13 , pp. 593-597
    • Kellermann, S.A.1    Green, L.L.2
  • 67
    • 0028222932 scopus 로고
    • Antigen-specific human antibodies from mice comprising four distinct genetic modifications
    • N. Lonberg et al. Antigen-specific human antibodies from mice comprising four distinct genetic modifications Nature 368 1994 856-859
    • (1994) Nature , vol.368 , pp. 856-859
    • Lonberg, N.1
  • 69
    • 0037323323 scopus 로고    scopus 로고
    • Developing novel oncolytic adenoviruses through bioselection
    • W. Yan et al. Developing novel oncolytic adenoviruses through bioselection J. Virol. 77 2003 2640-2650
    • (2003) J. Virol. , vol.77 , pp. 2640-2650
    • Yan, W.1
  • 70
    • 0035902471 scopus 로고    scopus 로고
    • Enhanced antitumor efficacy of a herpes simplex virus mutant isolated by genetic selection in cancer cells
    • S. Taneja J. MacGregor S. Markus S. Ha I. Mohr Enhanced antitumor efficacy of a herpes simplex virus mutant isolated by genetic selection in cancer cells Proc. Natl. Acad. Sci. USA 98 2001 8804-8808
    • (2001) Proc. Natl. Acad. Sci. USA , vol.98 , pp. 8804-8808
    • Taneja, S.1    MacGregor, J.2    Markus, S.3    Ha, S.4    Mohr, I.5
  • 71
    • 0037452445 scopus 로고    scopus 로고
    • Utility of physiologically based pharmacokinetic models to drug development and rational drug discovery candidate selection
    • F.P. Theil T.W. Guentert S. Haddad P. Poulin Utility of physiologically based pharmacokinetic models to drug development and rational drug discovery candidate selection Toxicol. Lett. 138 2003 29-49
    • (2003) Toxicol. Lett. , vol.138 , pp. 29-49
    • Theil, F.P.1    Guentert, T.W.2    Haddad, S.3    Poulin, P.4
  • 72
    • 1042302103 scopus 로고    scopus 로고
    • Early prediction of drug metabolism and toxicity: Systems biology approach and modeling
    • A. Bugrim T. Nikolskaya Y. Nikolsky Early prediction of drug metabolism and toxicity: Systems biology approach and modeling Drug Discovery Today 9 2004 127-135
    • (2004) Drug Discovery Today , vol.9 , pp. 127-135
    • Bugrim, A.1    Nikolskaya, T.2    Nikolsky, Y.3
  • 73
    • 0034002261 scopus 로고    scopus 로고
    • Role of the development scientist in compound lead selection and optimization
    • S. Venkatesh R.A. Lipper Role of the development scientist in compound lead selection and optimization J. Pharm. Sci. 89 2000 145-154
    • (2000) J. Pharm. Sci. , vol.89 , pp. 145-154
    • Venkatesh, S.1    Lipper, R.A.2
  • 75
    • 0036764768 scopus 로고    scopus 로고
    • Dual targeting of adenoviral vectors at the levels of transduction and transcription enhances the specificity of gene expression in cancer cells
    • B.G. Barnett B.W. Tillman D.T. Curiel J.T. Douglas Dual targeting of adenoviral vectors at the levels of transduction and transcription enhances the specificity of gene expression in cancer cells Mol. Ther. 6 2002 377-385
    • (2002) Mol. Ther. , vol.6 , pp. 377-385
    • Barnett, B.G.1    Tillman, B.W.2    Curiel, D.T.3    Douglas, J.T.4
  • 76
    • 0034086730 scopus 로고    scopus 로고
    • Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein
    • K. Doronin K. Toth M. Kuppuswamy P. Ward A.E. Tollefson W.S. Wold Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein J. Virol. 74 2000 6147-6155
    • (2000) J. Virol. , vol.74 , pp. 6147-6155
    • Doronin, K.1    Toth, K.2    Kuppuswamy, M.3    Ward, P.4    Tollefson, A.E.5    Wold, W.S.6
  • 77
    • 0034917855 scopus 로고    scopus 로고
    • Wild-type adenovirus decreases tumor xenograft growth, but despite viral persistence complete tumor responses are rarely achieved - Deletion of the viral E1b-19-kD gene increases the viral oncolytic effect
    • D. Harrison H. Sauthoff S. Heitner J. Jagirdar W.N. Rom J.G. Hay Wild-type adenovirus decreases tumor xenograft growth, but despite viral persistence complete tumor responses are rarely achieved - Deletion of the viral E1b-19-kD gene increases the viral oncolytic effect Hum. Gene Ther. 12 2001 1323-1332
    • (2001) Hum. Gene Ther. , vol.12 , pp. 1323-1332
    • Harrison, D.1    Sauthoff, H.2    Heitner, S.3    Jagirdar, J.4    Rom, W.N.5    Hay, J.G.6
  • 78
    • 0034928059 scopus 로고    scopus 로고
    • Induced apoptosis supports spread of adenovirus vectors in tumors
    • J. Mi Z.Y. Li S. Ni D. Steinwaerder A. Lieber Induced apoptosis supports spread of adenovirus vectors in tumors Hum. Gene Ther. 12 2001 1343-1352
    • (2001) Hum. Gene Ther. , vol.12 , pp. 1343-1352
    • Mi, J.1    Li, Z.Y.2    Ni, S.3    Steinwaerder, D.4    Lieber, A.5
  • 79
    • 0036903141 scopus 로고    scopus 로고
    • Armed therapeutic viruses: Strategies and challenges to arming oncolytic viruses with therapeutic genes
    • T.W. Hermiston I. Kuhn Armed therapeutic viruses: Strategies and challenges to arming oncolytic viruses with therapeutic genes Cancer Gene Ther. 9 2002 1022-1035
    • (2002) Cancer Gene Ther. , vol.9 , pp. 1022-1035
    • Hermiston, T.W.1    Kuhn, I.2
  • 80
    • 0034628552 scopus 로고    scopus 로고
    • Deletion of the adenoviral E1b-19kD gene enhances tumor cell killing of a replicating adenoviral vector
    • H. Sauthoff S. Heitner W.N. Rom J.G. Hay Deletion of the adenoviral E1b-19kD gene enhances tumor cell killing of a replicating adenoviral vector Hum. Gene Ther. 11 2000 379-388
    • (2000) Hum. Gene Ther. , vol.11 , pp. 379-388
    • Sauthoff, H.1    Heitner, S.2    Rom, W.N.3    Hay, J.G.4
  • 81
    • 0035138689 scopus 로고    scopus 로고
    • A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency
    • K. Suzuki J. Fueyo V. Krasnykh P.N. Reynolds D.T. Curiel R. Alemany A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency Clin. Cancer Res. 7 2001 120-126
    • (2001) Clin. Cancer Res. , vol.7 , pp. 120-126
    • Suzuki, K.1    Fueyo, J.2    Krasnykh, V.3    Reynolds, P.N.4    Curiel, D.T.5    Alemany, R.6
  • 82
    • 0037598911 scopus 로고    scopus 로고
    • Expression of a fusogenic membrane glycoprotein by an oncolytic herpes simplex virus potentiates the viral antitumor effect
    • X. Fu L. Tao A. Jin R. Vile M.K. Brenner X. Zhang Expression of a fusogenic membrane glycoprotein by an oncolytic herpes simplex virus potentiates the viral antitumor effect Mol. Ther. 7 2003 748-754
    • (2003) Mol. Ther. , vol.7 , pp. 748-754
    • Fu, X.1    Tao, L.2    Jin, A.3    Vile, R.4    Brenner, M.K.5    Zhang, X.6
  • 83
    • 10744223476 scopus 로고    scopus 로고
    • VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents
    • D.F. Stojdl et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents Cancer Cell 4 2003 263-275
    • (2003) Cancer Cell , vol.4 , pp. 263-275
    • Stojdl, D.F.1
  • 84
    • 0344188096 scopus 로고    scopus 로고
    • An adenovirus mutant that replicates selectively in p53-deficient human tumor cells
    • J.R. Bischoff et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells Science 274 1996 373-376
    • (1996) Science , vol.274 , pp. 373-376
    • Bischoff, J.R.1
  • 85
    • 0030790684 scopus 로고    scopus 로고
    • Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells
    • R. Rodriguez E.R. Schuur H.Y. Lim G.A. Henderson J.W. Simons D.R. Henderson Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells Cancer Res. 57 1997 2559-2563
    • (1997) Cancer Res. , vol.57 , pp. 2559-2563
    • Rodriguez, R.1    Schuur, E.R.2    Lim, H.Y.3    Henderson, G.A.4    Simons, J.W.5    Henderson, D.R.6
  • 86
    • 0242290921 scopus 로고    scopus 로고
    • E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models
    • Y. Wang et al. E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models Nat. Biotechnol. 21 2003 1328-1335
    • (2003) Nat. Biotechnol. , vol.21 , pp. 1328-1335
    • Wang, Y.1
  • 87
    • 0034022622 scopus 로고    scopus 로고
    • Gene delivery from replication-selective viruses: Arming guided missiles in the war against cancer
    • T. Hermiston Gene delivery from replication-selective viruses: Arming guided missiles in the war against cancer J. Clin. Invest. 105 2000 1169-1172
    • (2000) J. Clin. Invest. , vol.105 , pp. 1169-1172
    • Hermiston, T.1
  • 88
    • 0033831080 scopus 로고    scopus 로고
    • A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer
    • F.R. Khuri et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer Nat. Med. 6 2000 879-885
    • (2000) Nat. Med. , vol.6 , pp. 879-885
    • Khuri, F.R.1
  • 89
    • 0032503659 scopus 로고    scopus 로고
    • A novel three-pronged approach to kill cancer cells selectively: Concomitant viral, double suicide gene, and radiotherapy
    • S.O. Freytag K.R. Rogulski D.L. Paielli J.D. Gilbert J.H. Kim A novel three-pronged approach to kill cancer cells selectively: Concomitant viral, double suicide gene, and radiotherapy Hum. Gene Ther. 9 1998 1323-1333
    • (1998) Hum. Gene Ther. , vol.9 , pp. 1323-1333
    • Freytag, S.O.1    Rogulski, K.R.2    Paielli, D.L.3    Gilbert, J.D.4    Kim, J.H.5
  • 90
    • 0035030198 scopus 로고    scopus 로고
    • Delivery systems intended for in vivo gene therapy of cancer: Targeting and replication competent viral vectors
    • E. Galanis R. Vile S.J. Russell Delivery systems intended for in vivo gene therapy of cancer: Targeting and replication competent viral vectors Crit. Rev. Oncol. Hematol. 38 2001 177-192
    • (2001) Crit. Rev. Oncol. Hematol. , vol.38 , pp. 177-192
    • Galanis, E.1    Vile, R.2    Russell, S.J.3
  • 91
    • 0036901290 scopus 로고    scopus 로고
    • Adenoviral vectors: Systemic delivery and tumor targeting
    • N.K. Green L.W. Seymour Adenoviral vectors: Systemic delivery and tumor targeting Cancer Gene Ther. 9 2002 1036-1042
    • (2002) Cancer Gene Ther. , vol.9 , pp. 1036-1042
    • Green, N.K.1    Seymour, L.W.2
  • 92
    • 0036376654 scopus 로고    scopus 로고
    • Cells as vehicles for cancer gene therapy: The missing link between targeted vectors and systemic delivery?
    • K. Harrington et al. Cells as vehicles for cancer gene therapy: The missing link between targeted vectors and systemic delivery? Hum. Gene Ther. 13 2002 1263-1280
    • (2002) Hum. Gene Ther. , vol.13 , pp. 1263-1280
    • Harrington, K.1
  • 93
    • 0030917202 scopus 로고    scopus 로고
    • ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents
    • C. Heise A. Sampson-Johannes A. Williams F. McCormick D.D. Von Hoff D.H. Kirn ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents Nat. Med. 3 1997 639-645
    • (1997) Nat. Med. , vol.3 , pp. 639-645
    • Heise, C.1    Sampson-Johannes, A.2    Williams, A.3    McCormick, F.4    Von Hoff, D.D.5    Kirn, D.H.6
  • 94
    • 0033012742 scopus 로고    scopus 로고
    • Preclinical development strategies for novel gene therapeutic products
    • A.M. Pilaro M.A. Serabian Preclinical development strategies for novel gene therapeutic products Toxicol. Pathol. 27 1999 4-7
    • (1999) Toxicol. Pathol. , vol.27 , pp. 4-7
    • Pilaro, A.M.1    Serabian, M.A.2
  • 95
    • 0035992427 scopus 로고    scopus 로고
    • Frequent administration of angiogenesis inhibitor TNP-470 (AGM-1470) at an optimal biological dose inhibits tumor growth and metastasis of metastatic human transitional cell carcinoma in the urinary bladder
    • K. Inoue M. Chikazawa S. Fukata C. Yoshikawa T. Shuin Frequent administration of angiogenesis inhibitor TNP-470 (AGM-1470) at an optimal biological dose inhibits tumor growth and metastasis of metastatic human transitional cell carcinoma in the urinary bladder Clin. Cancer Res. 8 2002 2389-2398
    • (2002) Clin. Cancer Res. , vol.8 , pp. 2389-2398
    • Inoue, K.1    Chikazawa, M.2    Fukata, S.3    Yoshikawa, C.4    Shuin, T.5
  • 96
    • 9144266295 scopus 로고    scopus 로고
    • Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse
    • S.R. Hingorani et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse Cancer Cell 4 2003 437-450
    • (2003) Cancer Cell , vol.4 , pp. 437-450
    • Hingorani, S.R.1
  • 97
    • 0033665576 scopus 로고    scopus 로고
    • Efficacy of a replication-selective adenovirus against ovarian carcinomatosis is dependent on tumor burden, viral replication and p53 status
    • C. Heise I. Ganly Y.T. Kim A. Sampson-Johannes R. Brown D. Kirn Efficacy of a replication-selective adenovirus against ovarian carcinomatosis is dependent on tumor burden, viral replication and p53 status Gene Ther. 7 2000 1925-1929
    • (2000) Gene Ther. , vol.7 , pp. 1925-1929
    • Heise, C.1    Ganly, I.2    Kim, Y.T.3    Sampson-Johannes, A.4    Brown, R.5    Kirn, D.6
  • 98
    • 0029830054 scopus 로고    scopus 로고
    • Natural resistance against tumors grafted into the brain in association with histocompatibility-class-I-antigen expression
    • T. Yamasaki et al. Natural resistance against tumors grafted into the brain in association with histocompatibility-class-I-antigen expression Int. J. Cancer 67 1996 365-371
    • (1996) Int. J. Cancer , vol.67 , pp. 365-371
    • Yamasaki, T.1
  • 99
    • 11144355464 scopus 로고    scopus 로고
    • Classification of proliferative pulmonary lesions of the mouse: Recommendations of the Mouse Models of Human Cancers Consortium
    • A.Y. Nikitin et al. Classification of proliferative pulmonary lesions of the mouse: Recommendations of the Mouse Models of Human Cancers Consortium Cancer Res. 64 2004 2307-2316
    • (2004) Cancer Res. , vol.64 , pp. 2307-2316
    • Nikitin, A.Y.1
  • 100
    • 0842332343 scopus 로고    scopus 로고
    • A genetically retargeted adenoviral vector enhances viral transduction in esophageal carcinoma cell lines and primary cultured esophageal resection specimens
    • C.J. Buskens et al. A genetically retargeted adenoviral vector enhances viral transduction in esophageal carcinoma cell lines and primary cultured esophageal resection specimens Ann. Surg. 238 2003 815-824
    • (2003) Ann. Surg. , vol.238 , pp. 815-824
    • Buskens, C.J.1
  • 101
    • 0242287933 scopus 로고    scopus 로고
    • Conditionally replicative adenovirus expressing a targeting adapter molecule exhibits enhanced oncolytic potency on CAR-deficient tumors
    • V.W. van Beusechem et al. Conditionally replicative adenovirus expressing a targeting adapter molecule exhibits enhanced oncolytic potency on CAR-deficient tumors Gene Ther. 10 2003 1982-1991
    • (2003) Gene Ther. , vol.10 , pp. 1982-1991
    • van Beusechem, V.W.1
  • 102
    • 0141632785 scopus 로고    scopus 로고
    • Novel immunocompetent murine tumor models for the assessment of replication-competent oncolytic adenovirus efficacy
    • G. Hallden et al. Novel immunocompetent murine tumor models for the assessment of replication-competent oncolytic adenovirus efficacy Mol. Ther. 8 2003 412-424
    • (2003) Mol. Ther. , vol.8 , pp. 412-424
    • Hallden, G.1
  • 103
    • 0036841845 scopus 로고    scopus 로고
    • TNFerade biologic: Preclinical toxicology of a novel adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene
    • H. Rasmussen et al. TNFerade biologic: Preclinical toxicology of a novel adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene Cancer Gene Ther. 9 2002 951-957
    • (2002) Cancer Gene Ther. , vol.9 , pp. 951-957
    • Rasmussen, H.1
  • 104
    • 0034150206 scopus 로고    scopus 로고
    • Evaluation of the biodistribution, persistence, toxicity, and potential of germ-line transmission of a replication-competent human adenovirus following intraprostatic administration in the mouse
    • D.L. Paielli et al. Evaluation of the biodistribution, persistence, toxicity, and potential of germ-line transmission of a replication-competent human adenovirus following intraprostatic administration in the mouse Mol. Ther. 1 2000 263-274
    • (2000) Mol. Ther. , vol.1 , pp. 263-274
    • Paielli, D.L.1
  • 105
    • 0036905005 scopus 로고    scopus 로고
    • Biosafety and product release testing issues relevant to replication-competent oncolytic viruses
    • M. Wisher Biosafety and product release testing issues relevant to replication-competent oncolytic viruses Cancer Gene Ther. 9 2002 1056-1061
    • (2002) Cancer Gene Ther. , vol.9 , pp. 1056-1061
    • Wisher, M.1
  • 106
    • 0036828125 scopus 로고    scopus 로고
    • Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): Phase II viral, immunologic, and clinical endpoints
    • T. Reid et al. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): Phase II viral, immunologic, and clinical endpoints Cancer Res. 62 2002 6070-6079
    • (2002) Cancer Res. , vol.62 , pp. 6070-6079
    • Reid, T.1
  • 107
    • 0035177690 scopus 로고    scopus 로고
    • Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: A phase I trial
    • T. Reid et al. Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: A phase I trial Gene Ther. 8 2001 1618-1626
    • (2001) Gene Ther. , vol.8 , pp. 1618-1626
    • Reid, T.1
  • 108
    • 0037314655 scopus 로고    scopus 로고
    • Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies
    • D. Makower et al. Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies Clin. Cancer Res. 9 2003 693-702
    • (2003) Clin. Cancer Res. , vol.9 , pp. 693-702
    • Makower, D.1
  • 109
    • 12944315014 scopus 로고    scopus 로고
    • Conditionally replicating herpes simplex virus mutant, G207, for the treatment of malignant glioma: Results of a phase I trial
    • J.M. Markert et al. Conditionally replicating herpes simplex virus mutant, G207, for the treatment of malignant glioma: Results of a phase I trial Gene Ther. 7 2000 867-874
    • (2000) Gene Ther. , vol.7 , pp. 867-874
    • Markert, J.M.1
  • 110
    • 0033193127 scopus 로고    scopus 로고
    • Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma
    • M.J. Mastrangelo et al. Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma Cancer Gene Ther. 6 1999 409-422
    • (1999) Cancer Gene Ther. , vol.6 , pp. 409-422
    • Mastrangelo, M.J.1
  • 111
    • 0035887153 scopus 로고    scopus 로고
    • A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy
    • T.L. DeWeese et al. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy Cancer Res. 61 2001 7464-7472
    • (2001) Cancer Res. , vol.61 , pp. 7464-7472
    • DeWeese, T.L.1
  • 112
    • 0036733759 scopus 로고    scopus 로고
    • Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer
    • S.O. Freytag et al. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer Cancer Res. 62 2002 4968-4976
    • (2002) Cancer Res. , vol.62 , pp. 4968-4976
    • Freytag, S.O.1
  • 113
    • 0033693231 scopus 로고    scopus 로고
    • Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: A phase II trial
    • J. Nemunaitis et al. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: A phase II trial Cancer Res. 60 2000 6359-6366
    • (2000) Cancer Res. , vol.60 , pp. 6359-6366
    • Nemunaitis, J.1
  • 114
    • 0034111270 scopus 로고    scopus 로고
    • Development of target-based antineoplastic agents
    • W.M. Stadler M.J. Ratain Development of target-based antineoplastic agents Invest. New Drugs 18 2000 7-16
    • (2000) Invest. New Drugs , vol.18 , pp. 7-16
    • Stadler, W.M.1    Ratain, M.J.2
  • 115
    • 10744227813 scopus 로고    scopus 로고
    • Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer
    • S.O. Freytag et al. Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer Cancer Res. 63 2003 7497-7506
    • (2003) Cancer Res. , vol.63 , pp. 7497-7506
    • Freytag, S.O.1
  • 116
    • 1342290237 scopus 로고    scopus 로고
    • AACR-NCL-EORTC International Conference on Molecular Targets and Cancer Therapeutics
    • T. Hermiston D. Kirn AACR-NCL-EORTC International Conference on Molecular Targets and Cancer Therapeutics Mol. Ther. 9 2004 144-146
    • (2004) Mol. Ther. , vol.9 , pp. 144-146
    • Hermiston, T.1    Kirn, D.2
  • 117
    • 0141973782 scopus 로고    scopus 로고
    • The phase III trial in the era of targeted therapy: Unraveling the "go or no go" decision
    • T.G. Roberts Jr. T.J. Lynch Jr. B.A. Chabner The phase III trial in the era of targeted therapy: Unraveling the "go or no go" decision J. Clin. Oncol. 21 2003 3683-3695
    • (2003) J. Clin. Oncol. , vol.21 , pp. 3683-3695
    • Roberts Jr., T.G.1    Lynch Jr., T.J.2    Chabner, B.A.3
  • 118
    • 0037811751 scopus 로고    scopus 로고
    • Gefitinib in recurrent non-small-cell lung cancer: An IDEAL trial?
    • D.H. Johnson C.L. Arteaga Gefitinib in recurrent non-small-cell lung cancer: An IDEAL trial? J. Clin. Oncol. 21 2003 2227-2229
    • (2003) J. Clin. Oncol. , vol.21 , pp. 2227-2229
    • Johnson, D.H.1    Arteaga, C.L.2
  • 119
    • 0037112181 scopus 로고    scopus 로고
    • Randomized discontinuation design: Application to cytostatic antineoplastic agents
    • G.L. Rosner W. Stadler M.J. Ratain Randomized discontinuation design: application to cytostatic antineoplastic agents J. Clin. Oncol. 20 2002 4478-4484
    • (2002) J. Clin. Oncol. , vol.20 , pp. 4478-4484
    • Rosner, G.L.1    Stadler, W.2    Ratain, M.J.3
  • 120
    • 10744220743 scopus 로고    scopus 로고
    • Approval summary: Imatinib mesylate capsules for treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase
    • J.R. Johnson et al. Approval summary: Imatinib mesylate capsules for treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase Clin. Cancer Res. 9 2003 1972-1979
    • (2003) Clin. Cancer Res. , vol.9 , pp. 1972-1979
    • Johnson, J.R.1
  • 121
    • 0345447210 scopus 로고    scopus 로고
    • Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy
    • R.C. Kane P.F. Bross A.T. Farrell R. Pazdur Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy Oncologist 8 2003 508-513
    • (2003) Oncologist , vol.8 , pp. 508-513
    • Kane, R.C.1    Bross, P.F.2    Farrell, A.T.3    Pazdur, R.4
  • 122
    • 12144287534 scopus 로고    scopus 로고
    • United States Food and Drug Administration drug approval summary: Gefitinib (ZD1839; Iressa) tablets
    • M.H. Cohen et al. United States Food and Drug Administration drug approval summary: Gefitinib (ZD1839; Iressa) tablets Clin. Cancer Res. 10 2004 1212-1218
    • (2004) Clin. Cancer Res. , vol.10 , pp. 1212-1218
    • Cohen, M.H.1
  • 123
    • 0037010079 scopus 로고    scopus 로고
    • Epidermal growth factor receptor-targeted therapy in colorectal cancer
    • P.J. O'Dwyer A.B. Benson III Epidermal growth factor receptor-targeted therapy in colorectal cancer Semin. Oncol. 29 2002 10-17
    • (2002) Semin. Oncol. , vol.29 , pp. 10-17
    • O'Dwyer, P.J.1    Benson III, A.B.2
  • 124
    • 1442332187 scopus 로고    scopus 로고
    • TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: A phase I study in patients with solid tumors
    • N. Senzer et al. TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: A phase I study in patients with solid tumors J. Clin. Oncol. 22 2004 592-601
    • (2004) J. Clin. Oncol. , vol.22 , pp. 592-601
    • Senzer, N.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.